Adavosertib


Adavosertib is an experimental anti-cancer drug candidate. It is a small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. It is being developed by AstraZeneca.It is being investigated as a treatment for pancreatic cancer with phase 1 trial. University of Michigan researchers are as of 2019 planning a phase 2 study.